Johnson & Johnson (NYSE:JNJ) issued its quarterly earnings results on Tuesday. The company reported $1.97 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.95 by $0.02, MarketWatch Earnings reports. The firm had revenue of $20.39 billion for the quarter, compared to analysts’ expectations of $20.27 billion. Johnson & Johnson had a return on equity of 34.62% and a net margin of 1.89%. Johnson & Johnson’s revenue was up 1.0% on a year-over-year basis. During the same quarter last year, the business posted $1.74 EPS. Johnson & Johnson updated its FY 2019 guidance to $8.50-8.65 EPS and its FY19 guidance to $8.50-8.65 EPS.
NYSE:JNJ opened at $130.69 on Tuesday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.72. Johnson & Johnson has a fifty-two week low of $118.62 and a fifty-two week high of $148.99. The stock has a market cap of $350.63 billion, a price-to-earnings ratio of 17.90, a price-to-earnings-growth ratio of 1.93 and a beta of 0.72.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 12th. Shareholders of record on Tuesday, February 26th will be paid a dividend of $0.90 per share. The ex-dividend date is Monday, February 25th. This represents a $3.60 annualized dividend and a yield of 2.75%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 49.32%.
In other Johnson & Johnson news, CAO Ronald A. Kapusta sold 3,643 shares of Johnson & Johnson stock in a transaction dated Thursday, December 13th. The stock was sold at an average price of $147.31, for a total transaction of $536,650.33. Following the transaction, the chief accounting officer now owns 13,641 shares of the company’s stock, valued at approximately $2,009,455.71. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Ronald A. Kapusta sold 8,441 shares of Johnson & Johnson stock in a transaction dated Thursday, November 8th. The shares were sold at an average price of $145.15, for a total value of $1,225,211.15. Following the transaction, the chief accounting officer now directly owns 17,284 shares in the company, valued at approximately $2,508,772.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 514,187 shares of company stock worth $74,951,528. Company insiders own 0.22% of the company’s stock.
Large investors have recently added to or reduced their stakes in the business. Stuart Chaussee & Associates Inc. lifted its holdings in shares of Johnson & Johnson by 20.7% during the 4th quarter. Stuart Chaussee & Associates Inc. now owns 466 shares of the company’s stock valued at $60,000 after buying an additional 80 shares during the last quarter. Selective Wealth Management acquired a new stake in shares of Johnson & Johnson during the 3rd quarter valued at about $105,000. CKW Financial Group lifted its holdings in shares of Johnson & Johnson by 18.8% during the 4th quarter. CKW Financial Group now owns 810 shares of the company’s stock valued at $105,000 after buying an additional 128 shares during the last quarter. WP Advisors LLC acquired a new stake in shares of Johnson & Johnson during the 2nd quarter valued at about $108,000. Finally, FNY Investment Advisers LLC acquired a new stake in shares of Johnson & Johnson during the 2nd quarter valued at about $117,000. 66.23% of the stock is currently owned by institutional investors.
A number of brokerages recently weighed in on JNJ. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $158.00 price target on the stock in a research note on Wednesday, November 28th. Morgan Stanley dropped their price target on Johnson & Johnson from $153.00 to $130.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 2nd. HC Wainwright reissued a “buy” rating on shares of Johnson & Johnson in a research note on Wednesday, October 17th. Finally, Credit Suisse Group set a $149.00 price target on Johnson & Johnson and gave the stock a “buy” rating in a research note on Sunday, October 14th. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and eight have assigned a buy rating to the company’s stock. Johnson & Johnson has a consensus rating of “Hold” and an average price target of $140.27.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.com-unik.info/2019/01/22/johnson-johnson-jnj-announces-earnings-results-beats-estimates-by-0-02-eps.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
Further Reading: Trading Strategy
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.